Oral Cancer News

Rx Target Found For HPV, Hep C And Related Cancers

Article Date: 15 Apr 2013 - 0:00 PDTSource: Medical News Today New discoveries by a team of scientists at LSU Health Sciences Center New Orleans for the first time reveal the inner workings of a master regulator that controls functions as diverse as the ability of nerve cells to "rewire" themselves in response to external stimuli and the mechanism by which certain viruses hijack normal cellular processes to facilitate their replication that can ultimately lead to cancer. The research was published in the Journal of Biological Chemistry. The complex genetic programs controlling the function of cells and the organs, nerves, and tissues that they form are expressed through the concerted contributions of some 30,000 unique proteins that constitute the human genome. Coordination of these proteins is controlled by a small set of master regulators that sense the environment of the cell and alter subtle features of the genetic programs to maintain metabolic balance, called cellular homeostasis. More radical alterations in the genetic programs due to gene mutation or in response to viral or bacterial infection frequently lead to conditions that can result in cancer or developmental defects. Lead investigator Dr. Virginia Ronchi, a postdoctoral fellow, and research associate Jennifer Klein, working in the laboratory of Dr. Arthur Haas, Professor and Head of Biochemistry and Molecular Biology at the LSU Health Sciences Center New Orleans School of Medicine, focused on the E6AP enzyme. This enzyme regulates the functions of several dozen different proteins involved in key homoeostatic processes. The E6AP protein belongs [...]

Charlotte Parker2013-05-09T13:10:26-07:00May, 2013|Oral Cancer News|

When a virus causes cancer, surgical robot can help

Source: www.bizjournals.com Author: James Ritchie Dr. Keith Wilson finds robotic surgery to be a good approach for removing tumors growing deep in the throat, as I recently reported. As it turns out, such tumors are often part of an alarming trend. They’re often caused by the sexually transmitted human papillomavirus, also known as HPV. In decades gone by, oral cancer was almost always associated with tobacco and alcohol use. It was typically a disease of old men. No more. Many of Wilson’s patients are nonsmokers and very light drinkers. “I can’t tell you how surprised people get,” said Wilson, who is chief of staff at University of Cincinnati Medical Center. “We’re seeing younger, more affluent and more highly educated patients.” High-risk HPVs cause virtually all cervical cancers. They have in recent years been implicated in oropharyngeal cancers. The oropharynx is the middle part of the throat, including the soft palate, the base of the tongue and the tonsils. About 63 percent of oropharyngeal cancers, or 11,000 cases per year, are associated with HPV infection, according to the American Dental Association. They’re frequently under age 50. Fortunately for such patients, HPV-associated oropharyngeal cancers have a better prognosis than those with other causes. Wilson said that cure rates can approach 90 percent. The da Vinci surgical robot is an effective tool for removing them, he said, because its long, joined arms can go where a surgeon’s hands can’t. But the machines, made by Sunnyvale, Calif.-based Intuitive Surgical Inc., are gaining some criticism. [...]

Oral Cancer Foundation News Team - A2013-05-03T14:06:57-07:00May, 2013|Oral Cancer News|

Radiosensitive Variation Key in HPV-Positive Head and Neck Cancer

Kate JohnsonMay 01, 2013Source: medscape.com GENEVA, Switzerland — Increased radiosensitivity likely contributes to improved outcomes in patients human papillomavirus (HPV)-positive head and neck squamous cell carcinomas (HNSCC), according to a new study. The findings point to a potential new approach that could enhance radiosensitivity further in these tumors, said Thorsten Rieckmann, PhD, from University Medical Center Hamburg Eppendorf in Germany. The study results, which he presented here at the 2nd European Society for Radiotherapy & Oncology (ESTRO) Forum, were also published online April 19 in Radiation and Oncology. The work was named 1 of 2 top-scoring abstracts at the ESTRO meeting. Dr. Rieckmann and colleagues compared a panel of 5 HPV-positive and 5 HPV-negative HNSCC cell lines, and demonstrated a statistically significant difference in average radiosensitivity between the 2 panels. However, in the HPV-positive cells, "we saw a very high variation in radiosensitivity, so clearly not every HPV-positive cell line is equally highly radiosensitive," Dr. Rieckmann told meeting delegates. "Therefore, caution should be urged when considering the deintensification of therapy via dose reduction," the researchers write. "Additional stratification within the subentity of HPV/p16-positive HNSCC may be necessary to more precisely predict individual tumor sensitivity." "Until we have molecular markers to predict radiosensitivity in HPV-positive HNSCC, pack-years of smoking, as suggested by Ang et al [N Engl J Med. 2010;363:24-35], are probably the best option," he told Medscape Medical News. The study demonstrated that a compromised DNA repair process is likely the reason behind the more favorable prognosis for patients with HPV-positive HNSCC treated [...]

Charlotte Parker2013-05-02T10:12:42-07:00May, 2013|Oral Cancer News|

Robotic surgery yields better quality of life for OC patients

Source: www.drbicuspid.com Author: Donna Domino, Features Editor Patients with oropharyngeal squamous cell carcinoma maintain a high quality of life a year after having transoral robotic surgery, according to a new study in the JAMA Otolaryngology -- Head & Neck Surgery (April 10, 2013). But elderly patients and those treated with adjuvant treatments such as external-beam radiation therapy and chemoradiation therapy do not, according to the study authors. Patients with oropharyngeal squamous cell carcinoma (OPSCC) have historically been treated with primary open surgery. However, cure rates were low, complication rates were high, and patient health-related quality of life (HRQOL) decreased, the researchers noted. Efforts to minimize morbidity and preserve organs have shifted treatments to primary external-beam radiation therapy or chemoradiation therapy, but these treatments are often associated with significant side effects and decreased quality of life, they added. Transoral laser microsurgery was pioneered in the 1990s by Wolfgang Steiner, MD, for laryngeal tumors and eventually adapted to the oropharynx. Since then, primary laser microsurgery has yielded favorable treatment outcomes for OPSCC patients, the researchers noted. Transoral robotic surgery (TORS), a more minimally invasive approach, was introduced in 2005 and has since been recognized as "oncologically sound," while also preserving function in OPSCC patients. Complication rates are low and swallowing function remains high, according to the study authors. Research has shown that speech, eating, social, and overall quality of life tend to decrease but remain high three months after TORS. However, long-term results among a significant number of patients are lacking. Long-term quality [...]

Oral Cancer Foundation News Team - A2013-04-25T08:14:15-07:00April, 2013|Oral Cancer News|

Be a trendsetter for oral cancer screenings

By Trish De Dios April 18, 2013Source: dentistryiq.com April is Oral Cancer Awareness Month. We are well-trained in hygiene school to perform a non-invasive visual and tactile oral cancer screening. We perform it on every patient we see and the patients of our school clinic are accustomed to the comprehensive nature of the exam we perform. We then are set free from the chains of dental hygiene school and unleashed into the world of professional private practice. Unfortunately, the transition from school to work can cause us to cut corners and be negligent in our oral cancer screening, due in part to the demands of being in private practice. Employers are often apprehensive of the time constraints of the exam and may be misinformed regarding how screenings would take place in their practice. My advice to the new grad is stay true to your ethical and clinical standards of care. Do not deviate from being thorough in your oral cancer screenings because of your newly acquired degree or work position. The most important part of a patient’s hygiene visit is this potentially life-saving exam, and once your patients and employer realize this, they will never undermine your clinical protocol. In addition to the great service you are providing your patients, it is a good business practice to create value in the dental hygiene appointment. Your patients are not just getting their teeth cleaned – convey to your employer and patients that when you are their hygienist, the hygiene visit will consist [...]

Charlotte Parker2013-04-24T16:51:37-07:00April, 2013|OCF In The News, Oral Cancer News|

Dose of reality: HPV is epidemic, which is odd since it is largely preventable

Source: www.sciencenews.org Author: Nathan Seppa There are two vaccines that guard against human papillomavirus, and they are in rare company among medical inventions — the vaccines prevent cancer. Only the hepatitis B vaccine can make the same claim. Cancer-causing HPV can trigger abnormal cell growth on the cervix, and cervical cancer still kills up to 4,000 U.S. women each year. The virus is also implicated in cancers occurring in the anus and the throat. All told, according to a 2011 study, 29 percent of sexually active U.S. girls and women carry a potentially cancer-causing HPV infection. Preteen and adolescent girls and boys are priority groups for vaccines that prevent human papillomavirus infection.© Jessica Rinaldi/Reuters/Corbis Back in 2006 and 2009, when the HPV vaccines Gardasil and Cervarix came onto the market, health officials dreamed of halting the spread of HPV, which is sexually transmitted, in a single generation. Scientists call such blanket coverage herd immunity — in which a pathogen gets vaccinated into oblivion, becoming so rare that even unvaccinated people are protected. With such heady potential, Gardasil, developed by Merck, and Cervarix, created by GlaxoSmithKline, should be an easy sell. They rev up a potent immunity against HPV 16 and 18, the two types of the virus that account for most cases of cervical cancer. Gardasil also prevents most genital warts. The immunity the vaccines provide is many-fold better than the weak protection engendered by a run-in with the virus itself, and since approval, both vaccines have proven [...]

Oral Cancer Foundation News Team - A2013-04-24T12:59:51-07:00April, 2013|Oral Cancer News|

Oral cancer cases higher in developing countries

Source: pakobserver.net Author: staff Oral cancer is the sixth most common cancer reported globally with roughly two thirds of these reported in developing countries, according to a report. Regardless of nationality, roughly half of long-term smokers will die from the effects of tobacco smoking, be it oral cancer, lung cancer or cardiovascular disease. In India 20 deaths per 100,000 are caused by oral cancer as compared to 10 deaths per 100,000 in the US and two deaths per 100,000 in the Middle East. Oral cancer, as well as updates in maxillofacial reconstruction, microneurosurgery, oral trauma, and facial cosmetic and orthognathic surgery, will be reviewed at the 2nd Oral and Maxillofacial Surgery Congress to be held in Dubai from May 1-5. Organised by Imedex in association with Arab Health, this year’s meeting will provide a number of new features that explore the rapidly reshaping field of oral and facial surgery. “The main causes of oral cancer have classically been related to smoking tobacco products and the Middle East has a higher rate of tobacco consumption then many other countries and this includes the use of the Shisha or Hookah,” said Dr Eric J Dierks, Clinical Professor of Oral and Maxillofacial Surgery at Oregon Health and Science University, USA and director of the Fellowship in Head and Neck Oncologic Surgery based at Legacy Emanuel Hospital in Portland, Oregon, who will be speaking at the congress. “There is a myth that smoking through a Shisha pipe is safer than smoking cigarettes but this [...]

Oral Cancer Foundation News Team - A2013-04-24T12:23:56-07:00April, 2013|Oral Cancer News|

Lower radiation reduces xerostomia in head/neck cancer patients

Source: www.drbicuspid.com Author: DrBicuspid Staff Lowering the radiation dose to the submandibular gland of patients with head and neck cancer decreases xerostomia, according to a study presented on April 20 at the European Society for Radiotherapy and Oncology (ESTRO) meeting in Geneva. Radiation oncologists at University Medical Center Utrecht (UMCU) showed for the first time that it is possible to reduce xerostomia in patients treated with radiotherapy for head and neck cancer if the radiation dose to a salivary gland (the submandibular gland) on the opposite side to the tumor is minimized, stated a university press release. It is the largest study yet to show a correlation between radiation doses to the submandibular glands and their output of saliva. Guidelines for the recommended maximum dose could potentially be issued for use in clinical practice to benefit patients, according to the researchers. Approximately 40% of head and neck cancer patients suffer from xerostomia in the long term, which causes problems with eating, sleeping, speech, tooth loss, and oral hygiene, leading to diminished quality of life, social isolation, and difficulty in the ability to work. Attempts to treat xerostomia and its consequences can be costly and are not very effective, the study noted. Therefore, the UMCU researchers looked at using intensity-modulated radiotherapy (IMRT) to treat the tumors and spare the submandibular gland on the opposite side of the tumor and both parotid glands. They also wanted to determine the maximum radiation dose and how the treatment would affect patients' xerostomia. They analyzed [...]

Oral Cancer Foundation News Team - A2013-04-24T12:19:16-07:00April, 2013|Oral Cancer News|

What the ‘rinse-and-spit’ oral cancer test could mean for dental professionals and their patients

Source: www.dentistryiq.com Author: Vicki Cheeseman, Associate Editor A new oral cancer “rinse-and-spit” test for the early detection of tumors could mean great things for dental professionals and their patients when the test becomes available for use in dental practices nationwide possibly as early as late 2014 or into 2015. The test, developed at the University of Miami Miller School of Medicine and exclusively licensed to Vigilant Biosciences, Inc., will be available as a low-cost, point-of-care screening test for the early detection of oral cancer, and is envisioned as a kit with a special oral rinse and test strip. The test strip detects proteins that are markers of oral cancer and are captured by the rinse. The markers may be present before a lesion is easily visible. Early detection tests are critical because the majority of patients present in late stage when cure rates reach only 40%. I asked Dr. Franzmann to explain how the test strip works. “The beauty of the test strip approach is that it is so simple for the patient and health-care professional to use. The technology behind the test strips has been around for many years and is used for many medical applications. The key is to know what to test for. Through our research, we discovered certain proteins, or markers, are present in the saliva in the early stages of squamous cell carcinoma, the most common head and neck cancer.” How early can tumors be detected with the test strip? Dr. Franzmann said, “The tumors [...]

Oral Cancer Foundation News Team - A2013-04-24T12:13:03-07:00April, 2013|Oral Cancer News|

HPV vaccination—reaping the rewards of the appliance of science

Source: bmj.comDate: April 18, 2013By: Simon Barton, clinical director National programmes could virtually eliminate certain diseases and substantially reduce costs. The optimism generated by scientific breakthroughs often turns to disappointment when applied to the real world of clinical care. It is therefore worth celebrating the extraordinary success of Australia’s national human papillomavirus (HPV) vaccination programme, which was implemented five years ago, as reported in the linked paper by Ali and colleagues (doi:10.1136/bmj.f2032).1 This analysis of data on 85 770 new patients from six Australian sexual health clinics shows a remarkable reduction in the proportion of women under 21 years of age presenting with genital warts—from 11.5% in 2007 to 0.85% in 2011 (P<0.001). Only 13 cases of genital warts were diagnosed in women under the age of 21 across all six health clinics in 2011. Such a reduction in this distressing disease caused by a sexually transmitted virus is a major public health achievement. Furthermore, the near eradication of genital warts in young Australian women will probably have a major impact on the costs of sexual healthcare. In 2007, Australia became one of the first countries to implement a nationally funded HPV vaccination programme for girls and young women with the quadrivalent vaccine. It started with the vaccination of girls aged 12 years in schools and a catch-up programme for girls and women aged 13-26 years. Quadrivalent vaccine protects against HPV types 6 and 11, which cause more than 90% of genital warts, in addition to HPV types 16 and 18, which [...]

Charlotte Parker2013-04-22T12:13:42-07:00April, 2013|Oral Cancer News|